Use of toll-like receptor 4 agonist crx-675 against pulmonary fibrosis

Abstract

The invention discloses an application of a stimulating agent CRX-675 of a Toll-like receiver 4 in resisting pulmonary fibrosis. By systematic study, the inventor discovers that a pulmonary fibrosis model is formed by injecting bleomycin (3U / Kg) into the trachea of C57BL / 6 mouse, after 7 days from model forming, CRX-675(10mg / kg / day) is injected into the abdominal cavity to the 21st day; by the histopathology and biochemical detection and other methods, when a TLR4 signal channel is activated, the death rate of the mouse injected with the bleomycin can be obviously reduced; when the TLR4 signal channel is activated, the inflammations and injuries of the lung induced by the bleomycin are obviously reduced, the pulmonary fibrosis caused by the bleomycin is reduced, the collagen deposition in the lung, the content of hydroxyproline and the expression of alpha-SMA are reduced, and the function of the lung of the mouse by pulmonary fibrosis is improved.

Description

technical field [0001] The invention designs a new application of Toll-like receptor 4 agonist CRX-675 in treating pulmonary fibrosis, and belongs to the technical field of medicine. Background technique [0002] Fibrosis is the main cause of disability and death in many chronic diseases, which seriously threatens people's health and life. According to relevant statistics in the United States, nearly 45% of the fatal diseases can be attributed to tissue fibroproliferative diseases. In recent years, the morbidity and mortality of pulmonary fibrosis have been on the rise. For example, after the clinical diagnosis of idiopathic pulmonary fibrosis is confirmed, the 3-year survival rate is less than 50%, and the 5-year mortality rate reaches 65%. Many chronic lung diseases, including asthma, chronic bronchitis, bronchiectasis, COPD, tuberculosis, lung cancer, interstitial lung disease, etc., are accompanied by fibrotic pathological changes. Pulmonary fibrosis can cause persist...

AI Technical Summary

Problems solved by technology

The exact pathogenesis of pulmonary fibrosis has not yet been fully elucidated

Except for pirfenidone, which has been approved for the treatment of interstitial pulmonary fibrosis in Japan (but not approved by the US FDA), there are currently no other effective drugs and treatments

Images